Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.

Ryo YamadaTakao OkawaKen MatsuoMakoto SuzukiNoriko MoriKiyoshi Mori

Published in: BMC nephrology (2019)

This case demonstrates that not only blockade of VEGF but also VEGFR2 antagonism may result in TMA, which is a rare but life-threatening complication of cancer treatment drug.

Keyphrases

vascular endothelial growth factor
endothelial cells
metastatic colorectal cancer
drug induced
adverse drug
emergency department